Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Posted: October 15, 2024 at 2:50 am

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies

Go here to read the rest:
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Related Posts